Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression

Marcela Vlková, Eva Fronková, Veronika Kanderová, Ales Janda, Sárka Ruzicková, Jirí Litzman, Anna Sedivá and Tomás Kalina

*J Immunol* published online 1 November 2010
http://www.jimmunol.org/content/early/2010/11/01/jimmunol.0903876

Supplementary Material [http://www.jimmunol.org/content/suppl/2010/11/01/jimmunol.0903876/6.DC1](http://www.jimmunol.org/content/suppl/2010/11/01/jimmunol.0903876/6.DC1)

Subscription Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

Permissions Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
Characterization of Lymphocyte Subsets in Patients with Common Variable Immunodeficiency Reveals Subsets of Naive Human B Cells Marked by CD24 Expression

Marcela Vlková,* Eva Froňková,†‡ Veronika Kanderová,†‡ Aleš Janda,† Šárka Ružičková,§ Jiří Litzman,* Anna Šedivá,* and Tomáš Kalina†‡

Increased proportions of naive B cell subset and B cells defined as CD27negCD21negCD38neg are frequently found in patients with common variable immunodeficiency (CVID) syndrome. Current methods of polychromatic flow cytometry and PCR-based detection of κ deletion excision circles allow for fine definitions and replication history mapping of infrequent B cell subsets. We have analyzed B cells from 48 patients with CVID and 49 healthy controls to examine phenotype, frequency, and proliferation history of naive B cell subsets. Consistent with previous studies, we have described two groups of patients with normal (CVID-21norm) or increased (CVID-21lo) proportions of CD27negCD21negCD38neg B cells. Upon further analyses, we found two discrete subpopulations of this subset based on the expression of CD24. The B cell subsets showed a markedly increased proliferation in CVID-21lo patients as compared with healthy controls, suggesting developmental arrest rather than increased bone marrow output. Furthermore, when we analyzed CD21pos naive B cells, we found two different subpopulations based on IgM and CD24 expression. They correspond to follicular (FO) I and FO II cells previously described in mice. FO I subset is significantly underrepresented in CVID-21lo patients. A comparison of the replication history of naive B cell subsets in CVID patients and healthy controls implies refined naive B cell developmental scheme, in which human transitional B cells develop into FO II and FO I. We propose that the CD27negCD21negCD38neg B cells increased in some of the CVID patients originate from the two FO subsets after loss of CD21 expression. The Journal of Immunology, 2010, 185: 000–000.

Common variable immunodeficiency (CVID) is a clinically heterogeneous group of primary Ab immunodeficiency diseases with an estimated prevalence of 1 in 30,000 with unclear etiology (1). It is characterized by decreased serum levels of IgG, IgA, and occasionally IgM and impaired Ab response to Ag stimulation and/or vaccination as well; it is usually accompanied by recurrent bacterial infections. Splenomegaly, granuloma formation, autoimmune disorders, and increased risk of malignancy are common complications (1, 2).

Although various abnormalities in number and function of T cells (3–7), B cells (8–13), and dendritic cells (14–16) have been described, the immunopathological mechanism leading to disturbed Ab production in CVID patients has not yet been defined.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10/S16.00

*Department of Clinical Immunology and Allergology, St. Anne’s University Hospital and Faculty of Medicine, Masaryk University, Brno; †Department of Pediatric Hematology and Oncology 2nd Medical Faculty and ‡Department of Immunology, 2nd Medical School, Charles University and University Hospital Motol; †Childhood Leukemia Investigation Prague; and ‡Laboratory of Diagnostics of Autoimmune Diseases, Institute of Biotechnology of Academy of Sciences of the Czech Republic, v.v.i., Prague, Czech Republic.

Received for publication December 2, 2009. Accepted for publication September 15, 2010.

This work was supported by Grants NT-11414, 10398-3, and MZ05FM2005 from the Czech Ministry of Health, Grant Agency of the Czech Republic 310/09/P058, and Research Plan AVOZ50520701 from the Ministry of Education, Sports, and Youth of the Czech Republic.

Address correspondence and reprint requests to Dr. Marcela Vlkova, Department of Clinical Immunology and Allergology, St. Anne’s University Hospital, Pekarská 53, 656 91 Brno, Czech Republic. E-mail address: marcela.vlkova@fnusa.cz

The online version of this article contains supplemental material.

Abbreviations used in this paper: CVID, common variable immunodeficiency; FC, flow cytometry; FO, follicular; GC, germinal center; KREC. κ-deleting recombination excision circle; MFI, mean fluorescence intensity.

Copyright © 2010 by The American Association of Immunologists, Inc. 0022-1767/10/S16.00
FIGURE 1. Scheme for gating B cell subsets. A, Gating of B cells is shown for a representative healthy donor. Lymphocytes were gated on forward and side light scatter and then on CD19 positivity, after which the remaining cells were divided into CD21pos and CD21neg subsets. Furthermore, naive B cells were defined as IgMpos and CD27neg. The CD21posIgMposCD27neg cells were subdivided into transitional and naive subsets. The CD21negIgMposCD27neg subset was increased in some CVID patients. The expression of IgM and CD24 defined two subsets of naive CD21pos (B) and CD21neg (C) B cells. Both subsets were observed in a CVID patient and in a healthy control. Overlays of CD19 histograms show differences between CD21negCD24neg (black) and CD21negCD24pos (gray) cells, whereas no difference was found between CD21posCD24neg (black) and CD21posCD24pos (gray) cells. D, Bar graph presenting the frequency of CD21posCD24pos/CD21negCD24neg cells in individual patients and controls.
B cells and CD21neg B cells) patients. To assess the developmental number of CD27posIgDnegIgMneg switched memory B cells and 75th percentiles, and the outlier range.

Results are expressed as the median, the 25th–75th percentiles, and the outlier range.

The p.C104R polymorphism was found in two patients, and the gene (cyclophilin ligand interactor TNFRSF13B) was analyzed in all patients. The p.C104R polymorphism was found in two patients, and the gene (cyclophilin ligand interactor TNFRSF13B) was analyzed in all patients.

Materials and Methods

Patients and healthy donors

We examined 48 CVID patients (25 females, 23 males; mean of age 43.4 ± 15.3 y, range 12–74 y) and 49 healthy donors (26 females, 23 males; mean of age 42.6 ± 13.6 y, range 20–78 y). In all CVID patients, B cells constituted >1% lymphocytes in the peripheral blood. The presence of polymorphisms in the TNFR family member transmembrane activator and cyclophilin ligand interactor gene (TNFRSF13B) was analyzed in all patients. The p.C104R polymorphism was found in two patients, and the.

Table I. Characterization of frequencies of basic B lymphocyte subpopulations and expression levels of CD19 for each examined group of CVID patients and healthy controls

<table>
<thead>
<tr>
<th>Subpopulations of Naive B cells</th>
<th>Healthy Controls (n = 49)</th>
<th>CVID-21lo Patients (n = 24)</th>
<th>CVID-21norm Patients (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Percentage from CD19pos B cells</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IgMposCD27neg</td>
<td>44.1 ± 11.1</td>
<td>75.0 ± 15.1</td>
<td>71.1 ± 13.9</td>
</tr>
<tr>
<td>CD21negIgMposCD27neg</td>
<td>39.9 ± 10.7</td>
<td>28.8 ± 13.0</td>
<td>59.8 ± 12.4</td>
</tr>
<tr>
<td>CD21negIgMposIgMposCD27neg</td>
<td>3.8 ± 2.6</td>
<td>27.0 ± 15.8</td>
<td>3.7 ± 2.3</td>
</tr>
<tr>
<td><strong>Transitional B cells</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD21posIgMposCD27neg</td>
<td>68.6 ± 18.6</td>
<td>975.5 ± 293.3</td>
<td>1011.6 ± 190.6</td>
</tr>
<tr>
<td><strong>Expression level of CD19 (MFI)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD21negIgMposCD27neg</td>
<td>557.1 ± 59.5</td>
<td>583.2 ± 119.7</td>
<td>571.1 ± 57.2</td>
</tr>
<tr>
<td>CD21negCD38negCD24pos</td>
<td>554.4 ± 119.9</td>
<td>676.9 ± 205.1</td>
<td>649.8 ± 118.6***</td>
</tr>
<tr>
<td>CD21negCD38negCD24posnorm</td>
<td>828.6 ± 186.0*</td>
<td>975.5 ± 293.3***</td>
<td>1011.6 ± 190.6***</td>
</tr>
</tbody>
</table>

Percentage from CD19pos B cells: Results are expressed as mean ± SD. Statistically different from healthy controls (*p < 0.00001; **p ≤ 0.0002).

Statistically different from CVID-21norm patients (**p = 0.00003). Expression level of CD19 (MFI): Results are expressed as mean ± SD. Statistically different from healthy controls (**p ≤ 0.0008).

MFI, mean fluorescence intensity.

The frequencies (A) and replication history (B) of naive B cell subpopulations for each examined group of CVID patients and healthy donors. Transitional B cells, IgMposCD27negCD24pos CD21negCD24neg; CD21negCD24neg; IgMposCD27negCD24pos CD21negCD24neg CD21negCD24pos B cells; CD21posCD24pos; IgMposCD27negCD24negCD21negCD24pos B cells. The number of cell divisions is expressed relative to the transitional B cell value in a healthy control sample (set as 0). Results are expressed as the median, the 25th–75th percentiles, and the outlier range. O, Outlier values; *, extreme values.

FIGURE 2. The frequencies (A) and replication history (B) of naive B cell subpopulations for each examined group of CVID patients and healthy donors.
p.I87N polymorphism was found in one patient; all three of the identified polymorphic genes were heterozygous. In 15 patients, ICOS gene mutations were analyzed with negative results.

The patients were on regular i.v. or s.c. Ig substitution. For patients who received i.v. Ig treatment, blood samples were always collected before the treatment. Informed consent was approved by the Medical Ethics Committee of St. Anne’s Faculty Hospital and was obtained before blood sampling.

CVID patients were divided into two groups based on the expression patterns of CD21 and CD38 on the patients’ B cells. Twenty-four patients fell into the CVID-21lo group, which was characterized by an increased proportion of B cells with low expression of CD21 and CD38 (>10%). The remaining 24 patients were placed in the CVID-21norm group, which was characterized by a normal frequency (<10%) of CD21lowCD38low B cells.

B cell staining and FC

PBMCs were isolated from 10 ml EDTA blood by density gradient centrifugation using a Ficoll-Paque (GE Healthcare Bio-Sciences, Uppsala, Sweden), and the isolated PBMCs were washed twice with PBS that was supplemented with 1% BSA. The PBMCs were incubated for 15 min in the dark with anti-CD27 Pacific Blue, anti-CD38 Alexa Fluor 700 (Exbio Praha a.s., Prague, Czech Republic), anti-human IgM FITC or anti-human IgM biotin (BD Pharmingen, San Jose, CA), followed by streptavidin-Qdot 605 (Invitrogen, Carlsbad, CA), anti-CD21 allophycocyanin (BD Pharmingen), anti-CD24 PE, and anti-CD19 PC7 (ImmunoTech, Marseille, France). After a final wash with PBS, two million PBMCs from each sample were acquired using a Cyan ADP flow cytometer (Dako, Glostrup, Denmark), as described in Kalina et al. (28).

**B cell response to a TLR9 agonist or a BCR agonist**

B lymphocytes were isolated from peripheral blood using the RosetteSep Human B Cell Enrichment Cocktail (StemCell Technologies, Rockford, IL) and Ficoll-Paque PLUS (GE Healthcare Bio-Sciences) density gradient centrifugation. Cells were stimulated with the TLR9 agonist CpG oligodeoxynucleotide 2006 at 2.5 μg/ml (Imgenex, San Diego, CA) with recombinant protein L at 10 μg/ml (Thermo Fisher Scientific, Rockford, IL) or with a negative control in RPMI 1640 medium that contained L-glutamine and 25 mM HEPES (Lonza, Basel, Switzerland) and supplemented with 10% heat-inactivated FBS (HyClone, South Logan, UT), 100 U/ml penicillin, 100 μg/ml streptomycin, 0.25 μg/ml Fungizone (Lonza Walkersville), and 10 ng/ml human rIL-4 (R&D Systems, Minneapolis, MN) at a starting concentration of 5 × 10^6 cells/ml.

**FIGURE 3.** Responses of FO B cells to BCR and TLR9 agonists reveal activated FO I and FO II phenotypes. Enriched B cells were stimulated in vitro with a BCR agonist (protein L) or a TLR9 agonist (CpG oligodeoxynucleotide 2006). A. Activation of B cells led either to a dominant FO II phenotype (IgM high) or to a combined FO II/FO I phenotype (IgM high and low) after 24 h. B. Proliferation was more pronounced in TLR9 agonist-stimulated B cells and was restricted to cells with the FO II phenotype after 3 d. C. Proportion of activated FO I or FO II cells in samples from three healthy donors in the presence of IL-4. No stimulation (CTRL), BCR agonist stimulation (BCR), or TLR9 agonist stimulation (TLR9).
Proliferation was detected with anti–Ki-67 PE (BD Biosciences, San Jose, CA) after permeabilization with BD FACSM™ Lysing Solution and BD FACSM™ Permeabilizing Solution 2, according to the manufacturer’s protocol (BD Biosciences), 3 d after in vitro stimulation.

The apoptosis after stimulation was assessed using annexin V Dy647 (ExBio Praha a.s.), and cell activation was detected by anti-CD69 PerCP-Cy5.5 (clone FN50; BioLegend, San Diego, CA).

**Investigation of B cell replication history**

B cell subsets were purified from the blood samples of 16 CVID patients (8 CVID-21lo, 8 CVID-21norm). To ensure that we had sufficient numbers of cells belonging to subpopulations that were not expanded in healthy controls, we used cells that were sorted from 11 buffy coats (instead of peripheral blood) as control subpopulations. The cells were sorted using a FACSAria flow cytometer (BD Biosciences) using the same set of mAbs that were described above. DNA from the sorted cell populations was extracted using the QIAamp DNA Blood Micro Kit (Qiagen, Hilden, Germany). We used the KREC detection method that was described previously (27) with in-house modifications, as follows. Unlike the method that was described by van Zelm et al. (27), we used a 8 cycle threshold method with a calibration sample consisting of sorted transitional B cells from a healthy donor that was split into two quantitative PCR reactions. The normalized 8 cycle threshold (KREC) values indicated the number of cell divisions in a given subpopulation in relation to the calibration sample. If the KREC amplification produced no signal within the sensitivity limit of the quantitative PCR reaction (e.g., the KRECs in a given sample were too dilute), we used the lowest possible number of cell divisions that was calculated using the number of intronRSS-KDE rearrangements in the sample.

**Statistical analysis**

The numerical differences between the subgroups were evaluated using the nonparametric Mann-Whitney U test and Wilcoxon test. In all statistical analyses, \( p < 0.05 \) was considered statistically significant. Student’s t test and Fisher’s exact test were used when appropriate. Statistical software STATISTICA (StatSoft, Tulsa, OK) version 7 was used.

**Results**

**Clinical characteristics of the CVID patient groups**

The following parameters were assessed for both patient groups: age, age of first symptoms, duration of the disease, presence of bronchiectasis, obstructive lung disease, chronic diarrhea, splenomegaly, lymphadenopathy, granulomatous disease, levels of Igs at the time of diagnosis, and presence of TNFRSF13B polymorphisms (Supplemental Table I). The only significant differences that we found were between the ages of the patients (CVID-21lo: mean = 52.5 y, SD = 11.5; CVID-21norm: mean = 35.5 y, SD = 13.9, \( p < 0.001 \)), the age of the first symptoms (CVID-21lo: mean = 33.5 y, SD = 10.8; CVID-21norm: mean = 18.5 y, SD = 15.5, \( p < 0.01 \)), and the presence of bronchiectasis (CVID-21lo: 12 patients [52%]; CVID-21norm: 6 patients [26%], \( p < 0.05 \)). No other differences were found.

The **CD27negCD21negCD38neg B cell subset is composed of two cell types that are defined by CD24 expression**

For cytometric analysis, all B cells were divided into naive and memory B cell populations, based on the expression of CD24 (Fig. 1A). We confirmed the previously described increased frequency of naive IgMposCD27neg B cells that was observed in subgroups of CVID patients (Table I). In **CVID-21lo patients**, the total B cell population contained an increased percentage of CD21negCD38neg B cells (referred to in this study as CD21negCD38neg B cells), compared with total B cells (11, 19, 20, 23). Our findings show that this elevation was restricted to the CD21negCD24pos subset in both healthy controls and CVID patients, although the elevation was more prominent in CVID patients (Fig. 1C, Table I).

Although **CVID-21lo patients** displayed relatively increased frequencies of naive IgMposCD27neg B cells, the increase was caused primarily by higher numbers of CD21negCD38neg B cells. The frequency of naive B cells with the typical CD21posCD27pos phenotype was actually decreased in **CVID-21lo patients** compared with the frequency of naive CD21pos B cells in healthy controls, whereas naive CD21pos B cells were significantly increased in **CVID-21norm patients** (Table I). The proportion of transitional B cells was higher in both groups of CVID patients compared with healthy controls (Fig. 2A), as already reported (20).

**Replication history of the naive B cell subset (excluding transitional B cells) showed a higher number of cell divisions in CVID patients**

The analysis of KRECs in transitional B cells showed that the number of cell divisions in both of the CVID subgroups was similar to that in healthy donors. However, in **CVID-21lo patients**, the CD21negCD24pos subset was found to undergo a higher number of divisions than in controls (Fig. 2B). The same pattern (although not significant) was found for the CD21negCD24pos B cell subset.

**Subsets of naive B cells corresponding to mouse FO I and FO II were found in humans and were underrepresented in CVID-21lo patients**

Two FO B cell populations, CD21negIgMlowIgDhighCD24pos and CD21negIgMhighIgDhighCD24high, that were designated FO I and FO II...
II, respectively, were recently described in mice. Cariappa et al. (25) distinguished mouse FO II cells from FO I cells according to the enhanced expression of IgM in FO II B cells. Both subpopulations showed increased expression of CD24. When we analyzed CD21<sup>pos</sup>CD27<sup>neg</sup>CD38<sup>int</sup> B cells, we found two subpopulations of cells: IgM<sup>high</sup>CD21<sup>pos</sup>CD27<sup>neg</sup>CD38<sup>int</sup>CD24<sup>pos</sup> and IgM<sup>int</sup>CD21<sup>pos</sup>CD27<sup>neg</sup>CD38<sup>int</sup>CD24<sup>int</sup>. We observed both subpopulations in human healthy donors and in CVID patients. The FO I/FO II difference was marked by enhanced CD24 expression on FO II-like cells in CVID patients, whereas in healthy individuals, the CD24 expression was only moderately increased on FO II cells (Fig. 1B). In mice, the distinction between FO subsets from marginal zone B cells is possible because of the enhanced expression of CD21 on marginal zone B cell subsets. Both subpopulations that we found in human peripheral blood had identical CD21 expression levels. The expression of CD21 was higher than it was in marginal zone-like B cells (IgM<sup>pos</sup>CD27<sup>pos</sup>CD38<sup>neg</sup>CD24<sup>high</sup>) (Supplemental Fig. 1). Because we observed two subpopulations with uniform expression of CD21, we assumed that the IgM<sup>high</sup>CD27<sup>neg</sup>CD38<sup>int</sup>CD24<sup>pos</sup> subset corresponds to FO II B cells and that the IgM<sup>int</sup>CD27<sup>neg</sup>CD38<sup>int</sup>CD24<sup>int</sup> subset corresponds to FO I B cells.

**Different responses to activation stimuli by FO I and FO II cells in human B cells**

The mouse model that was reported by Cariappa et al. (25, 26) suggests that FO I B cells develop from FO II B cells after strong BCR stimulation, and that FO II B cells can give rise to MZ-like cells. To support the phenotype distinction between FO I and FO II B cells in human B cells using functional data, we stimulated human B cells from healthy donors in vitro using a TLR9 agonist and a BCR agonist. We chose the *Peptostreptococcus magnus* protein L superantigen that binds to conserved κ L chains (29) as the BCR agonist because anti-IgM stimulation does not allow for a surface IgM-based definition of the responding B cells. The FO I and FO II definition was based solely on surface IgM in this experiment because CD24 is rapidly downregulated after activation by BCRs (30).

Both agonists triggered cell activation leading to CD69 upregulation and cell proliferation (Fig. 3A, 3B), whereas apoptosis was always below 9% and did not differ between stimulated or control cells at 2 h, 24 h, 48 h, or 3 d after stimulation (Supplemental Fig. 2). In line with the data for the mouse model, the BCR agonist led to the activation of ~55% of the naive B cells (corresponding to the proportion of κ L chain-positive B cells) that had acquired a predominantly FO I phenotype (Fig. 3A, 3C). In contrast, the TLR9 agonist activated all naive B cells and forced ~40% of cells to proliferate by day 3 after stimulation. Of note, all proliferating B cells displayed the FO II phenotype (Fig. 3B), which is in line with the lack of cell divisions that was documented in the FO I compartment ex vivo (Fig. 3C).

**The FO I compartment is disrupted in CVID patients**

The naive CD21<sup>pos</sup> B cell compartment is composed of FO I, FO II, and transitional B cells. The CVID-21lo patients had an
increased percentage of CD21<sup>pos</sup> B cells by definition, and thus had reciprocally decreased percentages of CD21<sup>pos</sup> B cells. We also found an elevated frequency of transitional B cells, but the frequency of FO II cells was similar to that in healthy controls. Fig. 4A shows that the FO I subset of cells formed a significantly lower proportion of B cells in CVID-21lo patients than in healthy donors. Thus, the decrease of FO I B cells accounts for the diminution of CD21<sup>pos</sup> B cells in CVID-21lo patients.

CVID-21norm patients presented with a higher frequency of CD21<sup>pos</sup> B cells, and both of the FO subsets were relatively increased (Fig. 4A).

The number of cell divisions for FO I and FO II cells in healthy controls was similar to those of transitional B cells (Fig. 4B). However, in CVID-21norm patients, the FO I and FO II cells divided more often than the FO B cells from healthy controls. FO II B cells also divided more often in CVID-21lo patients.

Discussion

Based on the combined analyses of healthy donors and CVID patients, we identified new subsets of human naive B cells that are defined by IgM and CD24 expression. First, we found subsets corresponding to mouse FO I and FO II cells (25, 31) in both healthy donors and CVID patients. Second, when analyzing the expanded CD21<sup>pos</sup>CD21<sup>neg</sup>CD38<sup>neg</sup> B cell subset in CVID-21lo patients, we were able to distinguish between two distinct populations, based on CD24 expression. A detailed analysis of peripheral blood using sensitive six-color FC also revealed that both CD21<sup>neg</sup>CD24<sup>pos</sup> and CD21<sup>neg</sup>CD24<sup>neg</sup> subsets were present in healthy donors, although they were present in low numbers. This finding was in contrast to a previous study by Rakhmanov et al. (23), which showed that the entire CD21<sup>pos</sup> population was also CD24<sup>neg</sup>. This was presumably caused by the fact that in that study, CD21<sup>neg</sup> cells were gated as CD19<sup>high</sup>, whereas we observed that the expression of CD19 in CD21<sup>neg</sup>CD24<sup>neg</sup> B cells was similar to that of naive and memory B cells, that is, lower than in CD21<sup>neg</sup>CD24<sup>neg</sup> B cells. CD24 represents the first pan-B cell molecule, and this GPI-anchored protein belongs to the heat-stable protein family. CD24 is downregulated after BCR activation, but its complete physiological function in B cells is unknown (32). Further studies will be needed to determine whether this molecule plays an essential role in naive B cell homeostasis. Currently, CD24 is used in FC as a marker of the different stages of naive B cell development.

Low numbers of cell divisions in the FO II (IgM<sup>high</sup>CD24<sup>pos</sup>) and FO I (IgM<sup>low</sup>CD24<sup>int</sup>) subpopulations from healthy control individuals indicate that these cells mature from transitional B cells in the absence of proliferation, whereas the CD21<sup>neg</sup>CD24<sup>pos</sup> and CD21<sup>neg</sup>CD24<sup>neg</sup> subsets showed a higher number of cell divisions (Fig. 5). The median numbers of divisions in the latter subsets correspond to the number of divisions in the population of naive B cells, defined as CD19<sup>pos</sup>IgD<sup>pos</sup>CD27<sup>neg</sup> by van Zelm et al. (27). In contrast to healthy donors, the CVID-21lo patients displayed not only an altered distribution of CD21<sup>pos</sup> B cells, but also elevated numbers of cell divisions in this compartment (Figs. 2, 5). We also found that the percentage of FO I B cells was strongly reduced in CVID-21lo patients. This may be explained by deficient responses to BCR signaling.

A marked decrease or absence of switched memory B cells and an increased frequency of naive B cells (e.g., CD21<sup>pos</sup>CD38<sup>neg</sup> in a subgroup of patients), together with an increased division rate, suggests a developmental arrest in normal bone marrow migration. Recent studies of a large cohort of patients showed that there was an increase in autoimmune phenomena in the CVID-21lo patient group (20). This may be a consequence of an oligoclonal expansion in the naive B cell compartment occurring during prolonged homeostatic proliferation or during proliferation in response to non-BCR stimuli, such as the TLR9 agonist that is exemplified in Fig. 3.

In contrast to the proportions of the examined B cell subsets in CVID-21lo patients, the proportions in CVID-21norm patients were inflated in all naive CD21<sup>pos</sup> B cell compartments. FO I and FO II B cell subsets were found to undergo a higher number of divisions than controls. This result may be due to prolonged homeostatic proliferation, as described above.

Of note, both groups of CVID patients had an increased proportion of transitional B cells compared with healthy donors (20). However, these cells did not show significantly increased numbers of cell divisions compared with control transitional B cells. Thus, we speculate that increased bone marrow migration represents an attempt to compensate for the reduced numbers of mature B cells in the periphery of these patients.

Replication history data from healthy donors, together with the findings from Cariappa et al. (25), point to a sequence of subset development from transitional B cells to FO II (IgM<sup>high</sup>CD24<sup>pos</sup>) cells, and later, to FO I (IgM<sup>low</sup>CD24<sup>rem</sup>) cells in the absence of cell division. The two later stage cell types can presumably give rise to the CD21<sup>neg</sup>CD24<sup>pos</sup> and CD21<sup>neg</sup>CD24<sup>neg</sup> subsets, respectively, as indicated by the fact that there are more cell divisions at these stages (Fig. 2B). Naive B cells in CVID patients fail to undergo the germinal center (GC) reaction and fail to enter the switched memory pool. These naive B cells were, however, shown to react to stimulation with anti-IgM plus IL-2, as demonstrated by the downregulation of CD24 (33), but the upregulation of the costimulatory molecules CD70 and CD86 was impaired. It is reasonable to suggest that the physiological (and likely repeated) stimulation of naive B cells by Ag and/or proinflammatory signals in CVID patients may lead to proliferation, after which these cells lose CD21 and become CD21<sup>neg</sup>CD24<sup>pos</sup> or CD21<sup>neg</sup>CD24<sup>neg</sup> cells (with added cell divisions) instead of undergoing the GC reaction. CD21<sup>neg</sup> B cells cannot participate in the GC reaction because CD21 expression is essential for GC formation, B cell FO dendritic cell contact, and B cell survival during the GC reaction (34).

In conclusion, we used IgM and CD24 surface expression patterns to refine our knowledge of naive peripheral B cell development, which is disrupted in CVID patients. We propose that cell proliferation without developmental progression is responsible for the accumulation of CD21<sup>neg</sup>CD38<sup>neg</sup> cells in a subset of CVID patients.

Disclosures

The authors have no financial conflicts of interest.

References

8 SUBSETS OF NAIVE B CELLS IN CVID


